Skip to content

Nd:YAG Laser Photobiomodulation for Neurosensory Recovery Following Bimaxillary Orthognathic Surgery

Nd:YAG Laser Photobiomodulation for Neurosensory Recovery Following Bimaxillary Orthognathic Surgery: A Randomised Sham-Controlled Double-Blinded Clinical Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07789821
Enrollment
36
Registered
2026-08-27
Start date
2026-09-01
Completion date
2028-12-31
Last updated
2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inferior Alveolar Nerve Injury, Infraorbital Nerve Injury, Neurosensory Disturbance Following Orthognathic Surgery, Photobiomodulation

Keywords

inferior alveolar nerve injury, photobiomodulation, Neurosensory disturbance following orthognathic surgery, Infraorbital nerve injury

Brief summary

This study investigates whether low-energy laser light therapy applied to the skin (photobiomodulation, PBM) can speed up recovery of sensation in the lower lip, chin, and cheek area following jaw surgery (bimaxillary orthognathic surgery). Numbness and altered sensation in these areas are common and expected side effects of jaw surgery, affecting approximately one third of patients at 12 months without active treatment. There is currently no proven non-invasive treatment to accelerate nerve recovery after jaw surgery. Eligible participants who develop numbness after jaw surgery will be randomly assigned to receive either active PBM laser treatment or an inactive sham laser treatment (6 sessions over 3 weeks). Neither the participant nor the assessor measuring recovery will know which treatment was received. All participants also receive standard postoperative care. The study aims to determine whether active PBM significantly reduces the time to functional sensory recovery compared with sham treatment, and to characterise recovery patterns using a standardised multicomponent neurosensory assessment battery over 12 months.

Detailed description

Neurosensory disturbances affecting the inferior alveolar nerve (IAN) and infraorbital nerve (ION) are well-recognised expected sequelae of bimaxillary orthognathic surgery, arising from surgical manipulation during sagittal split ramus osteotomy (SSRO) and Le Fort I osteotomy respectively. Published incidence data from a major Asian orthognathic centre (Alolayan and Leung, University of Hong Kong, PLoS ONE 2014, n=238) reported subjective IAN neurosensory disturbance rates of 35.4% at 6 months and 36.6% at 12 months following mandibular SSRO, and ION disturbance rates of 16.2% at 6 months and 13% at 12 months following Le Fort I osteotomy. These figures represent persistent clinically significant deficits in a substantial proportion of patients at a major Chinese-majority Asian tertiary centre, making them the most directly applicable published proxy for the expected NUH study population. Current management of post-orthognathic neurosensory deficits is expectant. In cases of non-recovery beyond six months, pharmacological options or microsurgical repair may be considered, but both carry limited efficacy data and significant procedural risk respectively. There is a clear unmet need for safe, non-invasive adjunctive interventions capable of accelerating neurosensory recovery. Photobiomodulation (PBM) involves the application of low-energy laser irradiation to stimulate mitochondrial cytochrome c oxidase, increasing ATP production, modulating reactive oxygen species, and upregulating neurotrophic factors including nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). These effects promote axonal regeneration, Schwann cell proliferation, and remyelination. A recent randomised controlled trial (Kayim et al., Journal of Oral and Maxillofacial Surgery, 2026) comparing Nd:YAG and diode laser PBM versus no-treatment control in 30 post-orthognathic patients reported IAN functional sensory recovery (FSR) rates of 90% in laser-treated groups versus 40% in controls at 12 months (log-rank p=0.001; adjusted hazard ratio 8.04, 95% CI 2.03-31.90). However, that study lacked a sham control, leaving placebo-adjusted efficacy unestablished. The present study addresses this critical gap with a fully sham-controlled, double-blinded design.

Interventions

DEVICENd:YAG laser photobiomodulation

Fotona Laser, Lightwalker, Nightlase

OTHERSham laser

Control

Sponsors

National University Hospital, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Biostatistician

Intervention model description

This study uses a parallel assignment model with two arms (active photobiomodulation and sham control) in a 1:1 ratio.

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age 21-80 years and above at time of orthognathic surgery. 2. Underwent bimaxillary orthognathic surgery (SSRO and Le Fort I osteotomy), without genioplasty 3. Willing and able to comply with the full 12-month follow-up schedule comprising 12 visits.

Exclusion criteria

1. Systemic diseases known to impair peripheral nerve regeneration, including diabetes mellitus (any type), peripheral neuropathy of any aetiology, multiple sclerosis, or other demyelinating disorders. 2. Pregnant women are excluded 3. Patients with cognitive impairment are excluded 4. History of hypersensitivity or adverse reaction to laser therapy of any type. 5. Surgical complication directly attributable to the orthognathic procedure that required reoperation or microsurgical nerve repair, as these represent a fundamentally different injury severity and recovery trajectory from the neurapraxic and axonotmetic injuries targeted by this study. 6. Genioplasty performed

Design outcomes

Primary

MeasureTime frameDescription
Time to functional sensory recovery (FSR) in the inferior alveolar nerve (IAN) distribution12 monthsFSR is defined as simultaneous achievement of all three of: (1) VAS = 0 across lateral IAN territory bilaterally using standardised blunt 21-gauge needle shaft; (2) Semmes-Weinstein monofilament ≤3.61 detectable at lateral IAN test sites bilaterally; and (3) Disk-Criminator static two-point discrimination positive at ≤15 mm at lateral IAN test sites bilaterally. Mandibular central incisor regions excluded due to bilateral innervation. The date of the first assessment at which all three criteria are simultaneously met is recorded as time to FSR.

Secondary

MeasureTime frameDescription
Time to functional sensory recovery (FSR) in the infraorbital nerve (ION) distribution12 monthsFSR is defined as simultaneous achievement of all three of: (1) VAS = 0 across lateral IAN territory bilaterally using standardised blunt 21-gauge needle shaft; (2) Semmes-Weinstein monofilament ≤3.61 detectable at lateral IAN test sites bilaterally; and (3) Disk-Criminator static two-point discrimination positive at ≤15 mm at lateral IAN test sites bilaterally. The date of the first assessment at which all three criteria are simultaneously met is recorded as time to FSR.
OHIP-1412 monthsOral Health Impact Profile-14 total score (0-56) and domain subscores; higher scores indicate greater oral health impact

Contacts

CONTACTChee Weng Yong, BDS, MDS
dencwy@Nus.edu.sg+65 97872962

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026